KC
JAZZ icon

Kepos Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kepos Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,806
Closed -$1.17M – 250
2019
Q4 		$1.17M Buy
+7,806
New +$1.06M 0.11% 99
2018
Q4 		– Sell
-37,616
Closed -$6.32M – 372
2018
Q3 		$6.32M Buy
+37,616
New +$6.47M 0.32% 75

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Kepos Capital's JAZZ Position: Q1 2020 in Review

Kepos Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 7,806 shares — an estimated $1.17M sold.

Kepos Capital first reported a position in JAZZ in Q3 2018 and held it in 2 quarters. The position peaked at $6.32M in Q3 2018. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Kepos Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Kepos Capital sold 7,806 Jazz Pharmaceuticals shares in Q1 2020, an estimated $1.17M.
  • Kepos Capital first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Kepos Capital's Jazz Pharmaceuticals position peaked at $6.32M in Q3 2018.
  • 407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.